Myogen GlaxoSmithKline agree to joint investment up to $100 million
GlaxoSmithKline to invest in Myogen
Westminster-based Myogen Inc. said Monday it will receive as much as $100 million from GlaxoSmithKline, as the drugmakers work together on two medicines that treat a lung condition.
Both drugs target pulmonary arterial hypertension, which affects about 200,000 people and, when untreated, can lead to heart failure.


